Selective androgen receptor modulator
LGD-4033 (Ligandrol)
LGD-4033 (ligandrol) is an unapproved oral selective androgen receptor modulator. Its half-life was 24 to 36 hours in a trial of 76 healthy men; the app uses 30 hours.1
LGD-4033 (Ligandrol) after one dose: 50% at ~30 h, 25% at 60 h, 12.5% at 90 h.
Drawn from the half-life in the app's model, ~30 h. The model's figures
- Compound
- LGD-4033 (Ligandrol)
- Symbol
- LGD
- Family
- SARMs
- Parts
- 14
- References
- 18
- Checked
- Last reviewed . Sources are listed below.
Overview
LGD-4033, also called ligandrol and VK5211, is an oral, nonsteroidal selective androgen receptor modulator (SARM) that has not been approved by the US Food and Drug Administration.2,3,4 Basaria and colleagues of Boston University School of Medicine and Ligand Pharmaceuticals (Journal of Gerontology: Series A, 2013) describe it as "a novel nonsteroidal, oral selective androgen receptor modulator" that "binds androgen receptor with high affinity and selectivity".1
Searching PubMed on 16 November 2026 with the string (LGD-4033 OR LGD4033 OR ligandrol OR VK5211) returned 52 records; by title and publication type, one is labelled a randomized controlled trial in people (Basaria and colleagues, 2013)1, and the others include human urine studies, case reports of liver injury, and studies in rats, horses and camels. ClinicalTrials.gov, searched the same day with the same names, returned one study, NCT02578095, a phase 2 trial in people recovering from hip fracture, registered by Viking Therapeutics as VK5211.5 The record does not use the name LGD-4033; Barbara and colleagues and Hoffmann and colleagues give VK5211 as another name for LGD-4033.5,3,6
How it works
Sources in this part
Basaria and colleagues write that "In animal models, LGD-4033 has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate".1 These are the trial authors' statements in the introduction of their paper; three of the authors are listed with Ligand Pharmaceuticals.1
Animal studies
In ovariectomised rats (15 per group) given ligandrol orally at 0.03, 0.3 or 3 mg/kg body weight for five weeks, Hoffmann and colleagues (University of Goettingen, Journal of Bone and Mineral Metabolism, 2023) reported improved bone structural properties and higher serum phosphorus, heart weight and uterus weight (0.43 ± 0.04 versus 0.11 ± 0.02 g) at 3 mg/kg compared with untreated ovariectomised rats, with biomechanical parameters not changed.6 The authors wrote that the "Low and medium doses did not affect bone tissue and had fewer side effects" and concluded that "Ligandrol at high dose showed a subtle anabolic effect on structural properties without any improvement in biomechanical properties of osteoporotic bones", adding that, considering side effects at this dose, further investigation for the therapy of postmenopausal osteoporosis needed to be reevaluated.6 In 14-week-old male rats (10 per group; two in the trained ligandrol group were withdrawn because of illness) given ligandrol 0.4 mg/kg by subcutaneous injection five times a week for 8 weeks, Vasilev and colleagues (Medical University Plovdiv, Naunyn-Schmiedeberg's Archives of Pharmacology, 2025) reported that ligandrol "reduced submaximal endurance, maximal oxygen consumption, concentrations of glucose, follicle-stimulating hormone, and testosterone" and "increased grip strength, triglycerides, and total cholesterol concentrations", with no effect on maximal sprinting speed, maximal time to exhaustion, or hematological and morphometric parameters.7 The authors wrote that "The negative effects of ligandrol treatment outweighed its benefits in this study", listed as limitations no baseline measurement of grip strength or the blood indicators, no plasma liver enzymes (AST and ALT) measured and one dose of one SARM, and declared no competing interests.7 None of these animal results is a result in people.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~30 h
- Bioavailability
- 95%
- Typical dose
- 5–10 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The app lists the half-life of LGD-4033 as about 30 hours. In the placebo-controlled trial of 76 healthy men, Basaria and colleagues wrote that "LGD-4033 displayed a prolonged elimination half-life (24–36 hours) and linear PK", a range that contains the app's figure.1 Serum concentrations "were nearly threefold higher on day 21 than on day 1, reflecting accumulation upon multiple dosing".1 The text of that paper lists the blood sampling times but reports no time to peak and no oral bioavailability percentage.1
| Parameter | Value | Note |
|---|---|---|
| Half-life, app's figure | ~30 hours | From the app's data |
| Half-life, healthy men1 | 24–36 hours | 0.1, 0.3 or 1.0 mg once daily for 21 days |
| Time to peak, app's figure | ~2 hours | From the app's data |
| Time to peak, sources | No plasma figure reported in the sources listed here | In urine, the highest LGD-4033 concentrations after single 1, 10 or 50 µg doses came 2 to 4 hours after ingestion8 |
| Bioavailability, app's figure | 95% | From the app's data |
| Bioavailability, sources | No percentage reported in the sources listed here | The trial gave LGD-4033 by mouth and measured serum concentrations1 |
Wagener and colleagues (German Sport University Cologne, Analytical and Bioanalytical Chemistry, 2022) measured LGD-4033 in urine, not blood, after micro-doses of 1, 10 or 50 µg in healthy men.8 They wrote that LGD-4033 and its metabolites "can be detected with the developed method for multiple days or weeks depending on the analyte"; in the single-dose study the longest detection window was for M5-a, with an earliest negative sample after 11 days at 50 µg and detection times that "varied notably between the volunteers".8 After five 50 µg doses in 5 days, M5-b was detected in all samples until the end of the study, 1004 and 1128 h after the last dose.8 A detection time in urine is not a half-life. The chart below uses the app's half-life of 30 hours and time to peak of 2 hours, with the once-daily schedule of the trial of Basaria and colleagues and of the registered hip fracture trial.1,5
Level over 1 weeks
Level, as a share of the peak after one 1 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 30 hours. It is not a measured level or a suggested dose.
Human studies
Deeper analysis: Basaria and colleagues, 2013
Basaria and colleagues (Boston University School of Medicine, University of Texas Medical Branch and Ligand Pharmaceuticals; Journal of Gerontology: Series A, 2013) ran a double-blind, placebo-controlled, ascending-dose study of the "safety and tolerability of escalating doses of LGD-4033 following repeated once-daily oral administration for 21 days".1 Of 389 men screened in person, 131 were eligible and 76 were randomized to placebo or 0.1, 0.3 or 1.0 mg daily for 21 days, followed by a 5-week observation period.1 The groups held 33 (placebo), 18 (0.1 mg), 11 (0.3 mg) and 14 (1.0 mg) men; 8 were lost to follow-up or discontinued and 68 completed the trial.1
The authors wrote that LGD-4033 "was safe and well tolerated at all doses".1 Headache, pain related to muscle biopsy and dry mouth were the most common adverse events and "did not show dose relationship"; more upper respiratory tract infections occurred in the 1.0 mg group, "but these events were not considered drug related".1 "No drug-related severe or serious adverse events occurred"; one cellulitis (placebo) and one gastroenteritis (0.3 mg) were severe and not considered related to study drug, and "There was no study discontinuation due to adverse events".1 Liver enzymes, hematocrit, prostate-specific antigen and electrocardiogram showed no clinically significant changes at any dose.1
Lean body mass increased dose dependently (p for trend = .04), averaging 1.21 kg at 1.0 mg (p = .047 versus placebo; analysed in 30 pooled placebo men and 17, 10 and 11 men at 0.1, 0.3 and 1.0 mg), and fat mass did not change significantly.1 Appendicular skeletal muscle mass was not significantly different from placebo (p for trend = .078), leg press strength rose by an average 68.3 N at 1.0 mg without a significant difference from placebo, and stair-climbing speed and power showed a trend that "did not achieve statistical significance".1 In men randomized to placebo or 0.3 mg daily, the change in fractional mixed-muscle protein synthesis, measured in the fasted state, did not differ significantly (0.033 ± 0.016 versus 0.031 ± 0.011, p = .99).1 Total testosterone and sex hormone-binding globulin fell dose dependently, free testosterone and follicle-stimulating hormone fell at 1.0 mg only, and hormone levels returned to baseline by day 56.1 HDL cholesterol decreased at doses of 0.3 mg and above (−10.4 mg/dL at 0.3 mg and −19.4 mg/dL at 1 mg, against −1.7 mg/dL on placebo), triglycerides decreased across all doses, and total and LDL cholesterol did not change significantly.1
The authors listed their own constraints: "The doses of study medication were administered sequentially in ascending order rather than in random order", the sample size "was not based on considerations of effect sizes", and the 3-week duration "was not designed to demonstrate maximal effects on skeletal muscle mass and muscle strength".1 The paper states "This trial was supported by Ligand Pharmaceuticals", and Zientek, Gordon and Kazmi are listed with Ligand Pharmaceuticals.1 Bhasin, the corresponding author of the trial, reported investigator-initiated research grants from several companies including Ligand in a 2017 JAMA paper.2
Deeper analysis: the registered hip fracture trial NCT02578095
ClinicalTrials.gov entry NCT02578095, sponsored by Viking Therapeutics and registered as VK5211-201, is titled "A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture".5 Eligible people were 65 or older, "ambulatory and recovering from a hip fracture", 3 to 7 weeks after injury; they were randomized to placebo or VK5211 0.5, 1.0 or 2.0 mg once daily for 12 weeks.5 In the four groups 28, 29, 26 and 25 people started (108 in all) and 19, 22, 17 and 17 completed.5 At baseline 83 of the 108 were women, the median age was 78 (range 64 to 94), 27 of 28 placebo people were White, and 78 of the 80 given VK5211 were Asian, none White.5
The registered primary outcome was the placebo-corrected percentage change in total body less head lean body mass on a whole-body DXA scan at week 12, analysed in an intention-to-treat population of 20, 27, 17 and 15 people, smaller than the randomized groups (15 of 25 at 2.0 mg).5 The posted least-squares mean differences from placebo were 4.75% (95% confidence interval 1.70 to 7.80, p = 0.0032) at 0.5 mg, 7.15% (3.76 to 10.54, p < 0.0001) at 1.0 mg and 9.08% (5.55 to 12.60, p < 0.0001) at 2.0 mg.5 Over a 24-week reporting window the record lists no deaths in any group, and serious adverse events in 4 of 28 people (placebo), 2 of 29, 3 of 26 and 5 of 25.5 In the record's table of other (non-serious) adverse events, counted per term and not summed to people, "Hepatic Enzyme Increased" was reported in 1 of 28 people on placebo, 1 of 29 at 0.5 mg, 1 of 26 at 1.0 mg and 4 of 25 at 2.0 mg, and "Alanine Aminotransferase Increase" in 0, 1, 0 and 1 of the same groups.5 One person each at 2.0 mg had the terms aspartate aminotransferase, blood alkaline phosphatase, liver function test abnormal and international normalised ratio increased, and the record gives no cause for any of these terms.5 The record posts only the primary outcome, states no limitations of its own, and its agreement section marks a restrictive agreement; the participants were recovering from a hip fracture with a median age of 78, so the result is not one in healthy young men.5 None of the 52 PubMed records returned by the search above is titled as a report of this trial.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Basaria and colleagues, 20131 | Double-blind, placebo-controlled, ascending-dose; sponsor Ligand Pharmaceuticals | 76 healthy men aged 21 to 50 years | 0.1, 0.3 or 1.0 mg once daily for 21 days, then 5 weeks of observation | Half-life 24–36 hours; no drug-related serious adverse events; lean body mass +1.21 kg at 1.0 mg (p = .047 versus placebo; 11 men analysed against 30 pooled placebo); fat mass and strength not significantly changed; HDL cholesterol and total testosterone lower |
| NCT02578095, results posted 20255 | Phase 2, randomized, double-blind, placebo-controlled, parallel group; sponsor Viking Therapeutics | 108 people recovering from hip fracture (eligible at 65 or older; median age 78, 83 women) | VK5211 0.5, 1.0 or 2.0 mg once daily for 12 weeks | Lean body mass difference from placebo 4.75%, 7.15% and 9.08% at 0.5, 1.0 and 2.0 mg; serious adverse events 4/28, 2/29, 3/26, 5/25; no deaths listed |
| Wen and colleagues, 2025 (systematic review)9 | Systematic review, six SARMs including LGD-4033 | 970 patients in nine studies, mean age 57.1 years | Mean follow-up 80 days (range 14 to 180) | Authors' conclusion for the six SARMs together: positive effect on physical performance and body composition, moderate rates of mild to moderate adverse effects, low rate of severe ones; pooled before and after means only (stair-climbing power 352.24 to 315.16 W, lean body mass 49.46 to 50.86 kg), with no control comparison and no LGD-4033-specific figures |
| Barbara and colleagues, 2020 (case report)3 | One patient; diagnosis by liver biopsy | 32-year-old man who denied other supplements and medications | 1 mL (10 mg) of Ligandrol daily for about 2 weeks | Total bilirubin 35.0 mg/dL; biopsy showed cholestatic hepatitis; improvement after stopping |
| Barbara and colleagues, 2020 (second case report)10 | One patient; both products contained RAD-140 (10 and 7.5 mg per capsule), the second also LGD-4033 5 mg per capsule | 52-year-old man who reported drinking bourbon and beer daily and using marijuana | Alpha Bolic 4 weeks, then Alpha Elite 3 weeks, 2 capsules daily | Total bilirubin 34.5 mg/dL; canalicular cholestasis on biopsy; improved about 3 months after stopping |
| Koller and colleagues, 2021 (two case reports)11 | Two patients; liver injury began after stopping the SARM, while on post-cycle products | A 19-year-old athlete and a 28-year-old man | Case 1: one ligandrol capsule daily for 4 weeks, amount unknown; case 2: ligandrol with ostarine over 3 months | Cholestatic injury on biopsy; both recovered after 3 months |
| Labban and colleagues, 2024 (case report)12 | One patient; other causes of liver injury tested for | 52-year-old man who also used pre-workout supplements and whey protein | Supplements containing LGD-4033 at "higher-than-recommended doses" for three months | Stopped 2 weeks before admission; treated with N-acetylcysteine, cholestyramine and ursodiol; total bilirubin 17 mg/dL on admission, 1 mg/dL 3 months after discharge |
| Cardaci and colleagues, 2022 (case report)13 | One man; measured before, during and after | 25-year-old man taking LGD-4033 and MK-677 together | LGD-4033 10 mg and MK-677 15 mg daily for 5 weeks | Pre-cycle to on-cycle change, both compounds together: total lean body mass +3.1%, HDL cholesterol −36.4%, alanine aminotransferase +205.0%, total testosterone −62.3% |
Doses reported in studies
| Source | Dose reported | Context |
|---|---|---|
| App's typical dose | 5–10 mg/day | From the app's data; none of the studies below reports this range as a studied dose |
| Basaria and colleagues, 20131 | Up to 22 mg in a previous single-dose study; 0.1, 0.3 or 1.0 mg daily in the trial | The 21-day trial in healthy men; 20 doses over 21 days |
| NCT025780955 | 0.5, 1.0 or 2.0 mg once daily | 12 weeks, people recovering from hip fracture |
| Barbara and colleagues, 20203 | 1 mL (10 mg) daily | The authors wrote that this is "10 to 100 times higher than the daily doses" in the trial |
| Cardaci and colleagues, 202213 | 10 mg daily, with MK-677 15 mg daily | 5 weeks, one man |
What products sold as LGD-4033 contained
Sources in this part
Van Wagoner and colleagues (Sports Medicine Research and Testing Laboratory, Salt Lake City; JAMA, 2017) bought and analysed 44 products marketed and sold on the internet as selective androgen receptor modulators.2 Only 23 (52%) contained one or more SARMs (Ostarine, LGD-4033 or Andarine), the amount of active compound matched the label in 18 of 44 (41%), no active compound was detected in 4 (9%), and substances not listed on the label were present in 11 (25%).2 The table lists eight products labelled as containing LGD-4033; for example, one labelled 4 mg per capsule contained 1 to 5 mg per capsule, one labelled 5 mg per capsule had "No active agents detected", a 60 mL solution labelled 30 mg/mL contained 1 to 10 mg/mL and a 30 mL solution labelled 10 mg/mL contained 0.1 to 1 mg/mL.2 The authors called it a "limited investigation" of products purchased from April to August 2016, and wrote that the results apply only to the products purchased.2
Side effects reported
Barbara and colleagues reported a total bilirubin of 35.0 mg/dL in a 32-year-old man after about 2 weeks of 10 mg daily, and wrote that "It is also possible that the Ligandrol that the patient took had other different unapproved drugs".3 In the single man in the Cardaci report, 5 weeks of LGD-4033 10 mg and MK-677 15 mg daily together was accompanied by pre-cycle to on-cycle changes in bone mineral density (−2.1%), alanine aminotransferase (+205.0%) and free testosterone (−85.7%), and the authors wrote that all variables returned to pre-cycle values after the cycle "apart from total fat mass, appendicular fat mass, bone area, total cholesterol and low-density lipoprotein-cholesterol".13 The FDA consumer update (content current as of 26 April 2023) states that studies and reports show SARMs are associated with "serious or life-threatening health problems", listing increased risk of heart attack or stroke, liver injury and acute liver failure, infertility and testicular shrinkage among them, and these statements are about SARMs as a class.14
Bloodwork and markers
Sources in this part
The app lists total testosterone, lipids and liver enzymes as markers to monitor. In the 21-day trial, total testosterone fell dose dependently, HDL cholesterol fell at 0.3 mg and above, and liver enzymes showed no clinically significant changes.1 In the registered hip fracture trial, the record's table of other adverse events lists, counted per term, hepatic enzyme increased in 1, 1, 1 and 4 people on placebo and at 0.5, 1.0 and 2.0 mg, alanine aminotransferase increase in 0, 1, 0 and 1, and four other liver-related terms in one person each at 2.0 mg, with no cause given.5
Regulatory and anti-doping status
The World Anti-Doping Agency's 2026 Prohibited List places LGD-4033 (ligandrol) in section S1.2, "Other anabolic agents", "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".15 Kintz and Gheddar (Journal of Analytical Toxicology, 2025) reported a female athlete whose urine contained bishydroxy-ligandrol at about 90 pg/mL and 200 pg/mL in specimens A and B; the Court of Arbitration for Sport accepted her explanation of exposure through the exchange of bodily fluids with her husband and lifted her provisional ban.16 In a consumer update with content current as of 26 April 2023, the FDA states that SARMs "are not FDA approved" and "cannot be legally marketed in the U.S. as a dietary supplement or drug at this time".14 In a warning letter dated 12 December 2025 to Dynamic Health Group, doing business as SARMS AMERICA, the FDA named "LGD-4033 Ligandrol" among products it said "are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act".4 Sport Integrity Australia stated in a November 2018 post that the Australian Therapeutic Goods Administration "classifies Ligandrol, like all SARMs, as a Schedule 4 drug".17
What is not known
Sources in this part
The sources listed here give no plasma time to peak and no oral bioavailability percentage for LGD-4033 in people, and the app's 95% bioavailability, 2-hour time to peak and 60-hour duration of activity have no cited measurement beside them here. The doses studied in the sources listed here are 0.1 to 1.0 mg daily for 21 days in healthy men and 0.5 to 2.0 mg daily for 12 weeks in people recovering from hip fracture; the app's typical dose of 5 to 10 mg/day is not a range those studies report.1,5 The one randomized trial in healthy men among the sources listed here ran 21 days.1
Frequently asked questions
What is the half-life of LGD-4033?
The app lists the half-life of LGD-4033 as about 30 hours, and Basaria and colleagues reported "a prolonged elimination half-life (24–36 hours)" in a placebo-controlled trial of 76 healthy men.1
Is LGD-4033 FDA approved?
In a consumer update with content current as of 26 April 2023, the FDA states that SARMs "are not FDA approved" and "cannot be legally marketed in the U.S. as a dietary supplement or drug at this time".14
Is LGD-4033 banned by WADA?
LGD-4033 (ligandrol) is named in section S1.2 of the WADA 2026 Prohibited List, which is prohibited at all times, in and out of competition.15
Has LGD-4033 been tested in people?
Does LGD-4033 lower testosterone?
In the 21-day trial, Basaria and colleagues reported a "dose-dependent suppression of total testosterone and sex hormone–binding globulin levels", with free testosterone suppressed at 1.0 mg only and levels back at baseline by day 56.1
Does LGD-4033 cause liver problems?
In the 21-day trial, liver enzymes showed no clinically significant changes at any dose.1 In the registered hip fracture trial, the record's table of other adverse events lists, counted per term, hepatic enzyme increased in 1, 1, 1 and 4 people on placebo and at 0.5, 1.0 and 2.0 mg, alanine aminotransferase increase in 0, 1, 0 and 1, and four other liver-related terms in one person each at 2.0 mg, with no cause given.5 Case reports describe liver injury in people who used LGD-4033 products, some with other products or substances named.3,11
How long can LGD-4033 be detected in urine?
In micro-dose studies in healthy men, the earliest negative urine sample for the longest-detected metabolite after a single 50 µg dose came after 11 days, with detection times that varied notably between volunteers.8 After five 50 µg doses in 5 days, M5-b was still detected at the end of the study, 1004 and 1128 h after the last dose.8 After 50 µg applied to the skin of five volunteers, the long-term metabolite M5b was detected up to 25 days.18
Guides, tools and comparisons
References
- Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci 2013;68(1). PMC4111291
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017. PMC5820696
- Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J 2020. PMC7304490
- US Food and Drug Administration. Warning Letter to Dynamic Health Group dba SARMS AMERICA, MARCS-CMS 719257, 12 December 2025. FDA warning letter
- Viking Therapeutics. Acute Hip Fracture Study in Patients 65 Years or Greater (VK5211-201). ClinicalTrials.gov NCT02578095, results posted 2025. NCT02578095
- Hoffmann DB, Derout C, Muller-Reiter M, et al. Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis. J Bone Miner Metab 2023. PMID 37407738
- Vasilev V, Georgieva K, Arabadzhiyska D, et al. Ligandrol lowers endurance and negatively affects lipid and hormonal profile of male rats. Naunyn Schmiedebergs Arch Pharmacol 2025. PMC12449370
- Wagener F, Guddat S, Gorgens C, et al. Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes. Anal Bioanal Chem 2022;414(2). PMC8724150
- Wen J, Syed B, Leapart J, et al. Selective Androgen Receptor Modulators (SARMs) Effects on Physical Performance: A Systematic Review of Randomized Control Trials. Clin Endocrinol (Oxf) 2025. PMID 39285652
- Barbara M, Dhingra S, Mindikoglu AL. Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033). ACG Case Rep J 2020. PMC7535764
- Koller T, Vrbova P, Meciarova I, et al. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin Cases 2021. PMC8180234
- Labban H, Kwait B, Paracha A, et al. LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults. Cureus 2024. PMC11485217
- Cardaci TD, Machek SB, Wilburn DT, et al. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Exp Physiol 2022. PMID 36303408
- US Food and Drug Administration. FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults. FDA Consumer Update. Content current as of 26 April 2023. FDA consumer update, current as of 26 April 2023
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA 2026. WADA 2026 list
- Kintz P, Gheddar L. Drug transfer during intimate moments can produce an adverse analytical finding during a doping control: A case report with ligandrol. J Anal Toxicol 2025. PMID 40338642
- Sport Integrity Australia. The rise of LGD-4033. Sport integrity blog, 6 November 2018. Sport Integrity Australia
- Korsmeier L, Krombholz S, Alhalabi H, et al. Exploring transdermal SARMs exposure: analysis of the elimination profiles and metabolism for doping control purposes. J Anal Toxicol 2025. PMID 40632609